## Clinical Context This patient has **stage IB endometrial cancer** (grade 2 endometrioid adenocarcinoma with invasion into the **inner half** of the myometrium, no cervical or extrauterine involvement). Key prognostic factors: - Grade 2 (intermediate-high risk) - Myometrial invasion: inner half (stage IB by 2009 FIGO — note: 2009 FIGO staging merged old IC into IB, so stage IB = any myometrial invasion ≥50%; however, the stem explicitly states "inner half" invasion, which under 2009 FIGO = stage IA) **Staging clarification (High-Yield):** Under **2009 FIGO staging** (current standard): - **Stage IA** = myometrial invasion < 50% (inner half) - **Stage IB** = myometrial invasion ≥ 50% (outer half) The stem states "invasion into the inner half of the myometrium" but labels it **stage IB** — this reflects the **older (1988) FIGO staging** where stage IB = inner half invasion. The question uses the older classification, and the final histopathology confirms "stage IB." We adjudicate based on the stated stage IB (inner half, grade 2) as given. ## Risk Stratification for Stage IB (Inner Half, Grade 2) Endometrial Cancer Per **ESMO/ESGO/ESTRO 2016 and NCCN guidelines**, risk groups for endometrioid endometrial cancer are: | Risk Group | Features | |---|---| | Low | Stage IA, grade 1–2, no LVSI | | Intermediate | Stage IA grade 3, or Stage IB grade 1–2 | | High-Intermediate | Stage IB grade 3, or stage II, or LVSI+ | | High | Stage III–IV, or non-endometrioid histology | **Stage IB grade 2 (inner half invasion) = Intermediate-risk group.** ## Adjuvant Therapy for Intermediate-Risk Endometrial Cancer **Key Point:** For **intermediate-risk** endometrial cancer (Stage IB, grade 1–2, endometrioid, no LVSI), the standard adjuvant treatment per PORTEC-2 trial and current guidelines is **vaginal brachytherapy (VBT) alone**. - **PORTEC-2 trial** (Nout et al., NEJM 2010): Compared EBRT vs. VBT in high-intermediate risk endometrial cancer. VBT was non-inferior to EBRT for vaginal recurrence control, with significantly less GI toxicity and better quality of life. EBRT did not improve overall survival. - **PORTEC-1 trial**: Showed that for intermediate-risk EC, adjuvant radiotherapy reduced local recurrence but did not improve survival vs. observation. **Clinical Pearl:** EBRT to the pelvis (with or without VBT) is reserved for **high-intermediate or high-risk** features: - Grade 3 histology with deep (outer half) invasion - Lymphovascular space invasion (LVSI) - Cervical stromal involvement (stage II) - Non-endometrioid histology (serous, clear cell, carcinosarcoma) - Stage III disease **Chemotherapy** (carboplatin + paclitaxel) is indicated for **high-risk or advanced-stage** disease (stage III–IV, or high-risk histologies), not for intermediate-risk stage IB endometrioid adenocarcinoma. ## Why Vaginal Brachytherapy Alone is Correct 1. **Reduces vaginal vault recurrence** — the most common site of failure in early-stage EC 2. **Avoids EBRT toxicity** — bowel dysfunction, bladder morbidity, secondary malignancies 3. **Non-inferior to EBRT** for local control in intermediate-risk disease (PORTEC-2) 4. **Guideline-recommended** — NCCN (Category 1), ESMO, FIGO for intermediate-risk stage IB grade 1–2 endometrioid EC 5. **No survival benefit** demonstrated with addition of EBRT in this risk group **High-Yield:** Combined EBRT + VBT (Option A) is used for **high-intermediate risk** (e.g., stage IB grade 3, or LVSI-positive) or **stage II** disease — NOT for grade 2 inner-half invasion without LVSI. [cite: PORTEC-2 Trial, NEJM 2010; NCCN Guidelines Uterine Neoplasms v2024; ESMO/ESGO/ESTRO Consensus Conference on Endometrial Cancer 2016]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.